| 引用本文:周璇1，葛灿侠2，陈羽3，钱晓君1，王艳玲1.小儿消积止咳口服液联合西药治疗儿童支气管哮喘临床效果的远期观察[J].世界中医药,2020,(11):. |
|
| 小儿消积止咳口服液联合西药治疗儿童支气管哮喘临床效果的远期观察 |
| Clinical Effects of Xiaoer Xiaoji Oral Liquid Combined with Western Medicine in the Treatment of Children'S Bronchial Asthma |
| 投稿时间：2020-03-02 |
| DOI：10.3969/j.issn.1673-7202.2020.11.020 |
| 中文关键词: 小儿消积止咳口服液 孟鲁司特钠 布地奈德 儿童哮喘 |
| English Keywords:Xiaoer Xiaoji Oral Liquid Montelukast sodium Budesonide Asthma in children |
| 基金项目:安徽省教育厅关于下达2017年度高校优秀拔尖人才培育资助项目（gxbjZD07）；2019年度合肥市卫生健康应用医学研究项目(SYKZ201906）；合肥市卫计委2018年应用研究项目（hwk2018zd016） |
|
| 摘要点击次数: 330 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究小儿消积止咳口服液联合西药治疗儿童支气管哮喘临床效果的远期影响。方法：选取2018年1月至2019年6月合肥市第三人民医院收治的支气管哮喘患儿66例作为研究对象，按照随机数字表法随机分为观察组和对照组，每组33例，观察组在观察组基础上加用小儿消积止咳口服液，分组治疗3个月，对照组在常规治疗基础上给予布地奈德雾化吸入和孟鲁司特钠颗粒口服治疗；比较2组患儿的临床疗效及炎性反应、免疫相关指标；院外随访6个月，复查并比较上述指标变化。结果：观察组的治疗总有效率明显优于对照组（P<0.05）；分组治疗3个月，观察组患儿EOS百分比、IgA、IgE及IgG水平明显改善且优于对照组及治疗前(P<0.05)；随访6个月观察组EOS百分比、IgA、IgE和IgG水平明显优于对照组（P<0.05），复发率略低于对照组（P>0.05）。结论：小儿消积止咳口服液联合孟鲁司特钠及布地奈德可长期降低支气管哮喘患儿炎性反应水平并改善其免疫功能，提高临床疗效，一定程度上降低复发率。 |
| English Summary: |
| To explore the long-term effects of Xiaoer Xiaoji Oral Liquid combined with Western medicine on children with bronchial asthma.Methods:A total of 66 children with bronchial asthma treated in Hefei Third People's Hospital from January 2018 to June 2019 were randomly divided into a contro group(n＝33)and an observation group(n＝33)according to random number table.In the control group,budesonide aerosol inhalation and montelukast sodium granules were given orally.The observation group was treated with Xiaoer Xiaoji Oral Liquid on the basis of the control group.The groups were treated for 3 months.Clinical efficacy,and immune related indicators were compared; In the follow-up for 6 months outside the hospital,the above indicators were compared.Results:The total effective rate in the observation group was significantly better than that in the control group(P<0.05).After 3 months of group treatment,the percentage of EOS,levels of IgA,IgE and IgG in the observation group were significantly improved and better than those in the control group and before treatment(P<0.05); EOS percentage,IgA,IgE,and IgG levels in the observation group were significantly better than those in the control group(P<0.05),and the recurrence rate was slightly lower than that in the control group(P>0.05).Conclusion:Xiaoer Xiaoji Oral Liquid combined with montelukast sodium and budesonide can reduce the inflammation level,improve the immune function of children with bronchial asthma in a long-term,improve the clinical efficacy,and reduce the recurrence rate to a certain extent. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
